En Es
Categories

Industry News


DIAsource Immunoassays Enters Agreement with ZenTech for RIA Products

By Labmedica International staff writers
31 Jul 2018

Image: DIAsource Immunoassays has entered into an agreement with ZenTech for its portfolio of radioimmunoassays (RIA) products (Photo courtesy of iStock).DIAsource Immunoassays (Brabant Wallon, Belgium), a BioVendor group company, has entered into a strategic agreement with ZenTech (Angleur, Belgium) under which ZenTech will transfer its portfolio of radioimmunoassays (RIA) products to DIAsource, securing their continued production and sales.

DIAsource ImmunoAssays is a diagnostics company specialized in the development, manufacturing, and sales and distribution of immunoassay tests and open instrumentation solutions for clinical diagnostics. It delivers manual RIA and ELISA kits and open automation solutions to the international markets, and has a portfolio of over 190 ELISA and 140 RIA assays. ZenTech specializes in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening. It has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity.

Both the companies have long standing collaborations for more than 15 years, with DIAsource already successfully managing a part of the commercialization of the ZenTech portfolio. The current transfer of RIA products from ZenTech to DIAsource is in line with their strategies. The portfolio to be transferred includes the complete line of special RIAs with thyroid markers and markers for fertility and salt balance. Effective July 24, 2018, DIAsource Immunoassays has assumed commercial ownership of ZenTech’s RIA product portfolio and will service clients from order to shipment, while ZenTech will remain the manufacturer during the transition period in which the production will be transferred to DIAsource. The transfer of production will be done in close collaboration and in phases to be concluded by September 30, 2019.

“Historically, ZenTech had a background and expertise in radioimmunoassays. However, when ZenTech acquired the Belgian company Gamma in 2011, it got access to new technologies and entered the market of newborn screening and early life stage diseases,” said Jean-Claude Havaux, Chairman of the Board, ZenTech. “Today's acquisition of the RIA products by ZenTech’s commercial partner DIAsource will guarantee RIA customers are offered long-term service and excellence in logistics worldwide. This transaction will give ZenTech the opportunity to focus on new innovative product lines and other technologies such as molecular diagnostics and mass spectrometry.”

“This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012 and Viro-Immun ELISA and IFA product lines in 2017. DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This fourth acquisition in the RIA space demonstrates our commitment to the long term future servicing and support of our large RIA customer base worldwide,” said Jef Vangenechten, CEO of DIAsource Immunoassays. “We experience that RIA remains important as the gold standard for assays that are not available on automated systems or for parameters that require a higher analytical accuracy, whereby manual assays offer benefits in terms of quality and flexibility versus price. DIAsource now has a unique position by combining the most complete offering of RIA specialty assays on the market with the ability to offer various RIA automation solutions. Furthermore our manual assays also allow customization for life science research and screening,” added Vangenechten.



E-mail Print
FaceBook Twitter Google+ Linked in

DIASOURCE

Develops, manufactures, and markets clinical diagnostic products that focus on endocrinology and infectious diseases
Gold member
More info

More articles about DIASOURCE

19 Sep 2017
DIAsource ImmunoAssays SA Acquires Viro-Immun Diagnostics
DIAsource ImmunoAssays SA, which develops, sells and distributes clinical diagnostics products, has acquired Viro-Immun Diagnostics GmbH, a developer and manufacturer of laboratory diagnostics for the medical diagnosis of infectious and autoimmune diseases.
Read More

Additional news

23 Nov 2018
AI Predicts Alzheimer’s Disease Years before Diagnosis
A new study on the application of deep learning (DL) to detect changes in brain metabolism predictive of Alzheimer’s disease (AD) has found that artificial intelligence (AI) improves the ability of brain imaging to predict AD.
Read More
23 Nov 2018
UK to Set Up New GBP 10 Million Centre for Medical Imaging and AI
The UK’s London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare will train sophisticated artificial intelligence (AI) algorithms from NHS medical images and patient data, to create tools that will help clinicians speed up and improve diagnosis and care across a number of patient pathways, including dementia, heart failure and cancer.
Read More
23 Nov 2018
New AI Algorithm Enhances Polyp Detection in Colonoscopy Procedures
Researchers at Shanghai Wision AI Co., Ltd., a developer of computer-aided diagnostic algorithms and systems to improve the accuracy and effectiveness of diagnostic imaging, have announced results of a study validating a novel machine-learning algorithm that improves detection of adenomatous polyps during colonoscopy. The AI algorithm is built on the same network architecture that is used to develop self-driving cars and is designed to enable “self-driving” in colonoscopy procedures.
Read More
20 Nov 2018
Study Finds AI Falls Short When Analyzing Medical Data
A study conducted at the Icahn School of Medicine at Mount Sinai has found that artificial intelligence (AI) tools trained to detect pneumonia on chest X-rays suffered significant decreases in performance when tested on data from outside health systems. These findings suggest that unless AI in the medical space is carefully tested for performance across a wide range of populations, the deep learning models may not perform as accurately as expected.
Read More
20 Nov 2018
New AI Software for Brain Bleed Diagnosis Receives FDA Clearance
The US Food and Drug Administration (FDA) has given 510(k) clearance to the Accipio Ix intracranial hemorrhage (ICH) detection software developed by MaxQ AI, a clinical diagnostics intelligence platform company.
Read More
20 Nov 2018
Global Refurbished Medical Devices Market to Increase by 10% by 2023
The global refurbished medical devices market is expected to grow at a CAGR of over 10% during the forecast period 2019-2023, driven by the organized healthcare ecosystem in the developed economies. Moreover, privatization in the healthcare sector is increasing rapidly due to the inability of governments to invest efficiently in the sector, coupled with high demand for innovation and technology for superior healthcare services.
Read More
12 Nov 2018
ACR Data Science Institute Releases AI Use Cases to Accelerate AI Adoption
The American College of Radiology Data Science Institute has released a first-of-its-kind series of standardized artificial intelligence (AI) use cases that will accelerate medical imaging AI adoption. This continually updated, freely available use case series is the product of a previously missing and collaborative framework that enables efficient creation, implementation and ongoing improvement of radiological AI tools.
Read More
12 Nov 2018
Siemens Healthineers and Primary Health Care Enter Contract for In Vitro Diagnostics
Siemens Healthineers has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers, marking the largest contract ever for in vitro diagnostics testing in the country.
Read More
12 Nov 2018
OpenSight Augmented Reality System for Microsoft HoloLens Cleared by FDA
The FDA has granted 510(k) clearance to the OpenSight Augmented Reality System, making it the first AR medical solution for Microsoft HoloLens to be cleared for use in pre-operative surgical planning. Developed by Novarad, a provider of specialized enterprise imaging and workflow solutions, OpenSight renders 2D, 3D and 4D images of patients interactively, while accurately overlaying them directly onto the patient’s body.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions